Quest PharmaTech Inc. (CVE:QPT – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as C$0.04 and last traded at C$0.04, with a volume of 688986 shares. The stock had previously closed at C$0.03.
Quest PharmaTech Stock Performance
The company has a current ratio of 0.40, a quick ratio of 0.52 and a debt-to-equity ratio of 4.35. The stock has a market cap of C$5.07 million, a price-to-earnings ratio of -1.50 and a beta of 0.14. The stock’s 50 day moving average is C$0.03 and its two-hundred day moving average is C$0.03.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
Further Reading
- Five stocks we like better than Quest PharmaTech
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- P/E Ratio Calculation: How to Assess Stocks
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
